Related Experiment Videos
[Interferon beta-1b retinopathy during a treatment for multiple sclerosis]
S Sommer1, J C Sablon, M Zaoui
1CHR N.D. de Bonsecours, 1 pl Ph de Vigneulles, 57038 Metz cedex 1.
Journal Francais D'Ophtalmologie
|June 9, 2001
Summary
Interferon beta-1b, used for multiple sclerosis, may cause ocular adverse effects like retinopathy. Neutralizing antibodies can reduce treatment effectiveness, necessitating testing during treatment failure.
Area of Science:
- Ophthalmology
- Neurology
- Immunology
Background:
- Interferon alpha has known ocular adverse effects in malignant diseases and viral hepatitis.
- Interferon beta-1b is a treatment for multiple sclerosis.
Observation:
- This study reports bilateral retinopathy in a patient undergoing interferon beta-1b treatment for multiple sclerosis.
- This is the first reported instance of ocular effects with interferon beta-1b in multiple sclerosis.
Findings:
- The development of neutralizing antibodies during interferon beta-1b therapy can diminish its therapeutic efficacy.
- Neutralizing antibodies should be tested when treatment failure is observed.
Implications:
- Ophthalmologists and neurologists should be aware of potential ocular complications associated with interferon beta-1b.
- Monitoring for neutralizing antibodies is crucial for managing multiple sclerosis patients treated with interferon beta-1b.